• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers
• Solvents and Organic Chemicals Organic Compounds cyanides/Cyanides

Introduction to 3-Fluoro-4-(trifluoromethoxy)benzaldehyde (CAS No. 473917-15-6)

3-Fluoro-4-(trifluoromethoxy)benzaldehyde, identified by the Chemical Abstracts Service Number (CAS No.) 473917-15-6, is a fluorinated aromatic aldehyde that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to a class of molecules characterized by the presence of both fluorine and methoxy substituents on a benzene ring, which are known to modulate the electronic properties and biological activity of the molecule. The structural features of this compound make it a valuable intermediate in the synthesis of various pharmacologically active agents.

The fluorine atom in 3-Fluoro-4-(trifluoromethoxy)benzaldehyde plays a crucial role in enhancing the metabolic stability and binding affinity of drug candidates. Fluorinated compounds are widely recognized for their ability to improve pharmacokinetic profiles, including bioavailability and half-life, which are critical factors in drug development. Additionally, the trifluoromethoxy group contributes to the lipophilicity and electronic distribution of the molecule, influencing its interactions with biological targets. These characteristics make 3-Fluoro-4-(trifluoromethoxy)benzaldehyde a promising building block for designing novel therapeutic agents.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various diseases, including cancer, inflammation, and infectious disorders. The benzaldehyde core structure is frequently employed in medicinal chemistry due to its versatility in forming hydrogen bonds and its ability to serve as a precursor for more complex scaffolds. The introduction of fluorine and methoxy groups into this framework has opened up new avenues for drug discovery, particularly in the design of kinase inhibitors and other enzyme-targeting molecules.

One of the most compelling aspects of 3-Fluoro-4-(trifluoromethoxy)benzaldehyde is its utility as a key intermediate in the synthesis of fluorinated aldehydes, which are essential for constructing biologically active compounds. For instance, researchers have utilized this compound to develop novel inhibitors of tyrosine kinases, which are implicated in various cancers. The fluorine atom's ability to increase binding affinity has been leveraged to enhance the potency of these inhibitors against their target enzymes. Furthermore, the trifluoromethoxy group has been shown to improve selectivity, reducing off-target effects and minimizing side reactions.

The pharmaceutical industry has increasingly recognized the importance of fluorinated compounds in drug development due to their favorable pharmacokinetic properties. 3-Fluoro-4-(trifluoromethoxy)benzaldehyde exemplifies this trend, as it serves as a versatile scaffold for creating novel therapeutics. Its structural features allow for modifications that can fine-tune biological activity, making it an invaluable tool for medicinal chemists. Recent studies have demonstrated its application in synthesizing compounds with enhanced efficacy against resistant strains of pathogens, highlighting its potential in addressing emerging therapeutic challenges.

From a synthetic chemistry perspective, 3-Fluoro-4-(trifluoromethoxy)benzaldehyde offers unique advantages due to its reactivity and stability under various conditions. The presence of both electron-withdrawing and electron-donating groups facilitates diverse chemical transformations, enabling access to a wide range of derivatives. This flexibility has been exploited in the development of libraries of compounds for high-throughput screening (HTS), allowing researchers to identify potent leads rapidly. Additionally, the compound's compatibility with modern synthetic methodologies makes it an attractive choice for industrial-scale production.

The impact of fluorine substitution on biological activity has been extensively studied, and 3-Fluoro-4-(trifluoromethoxy)benzaldehyde is no exception. Research has shown that fluorine atoms can influence molecular interactions at both atomic and electronic levels, leading to significant improvements in drug properties. For example, fluorination can alter the conformational preferences of a molecule, enhancing its binding affinity or selectivity. This phenomenon has been observed in various drug classes, including antiviral and anticancer agents. The strategic use of fluorine atoms has thus become an integral part of modern drug design strategies.

In conclusion,3-Fluoro-4-(trifluoromethoxy)benzaldehyde (CAS No. 473917-15-6) represents a fascinating example of how structural modifications can significantly impact biological activity and pharmacokinetic properties. Its role as an intermediate in synthesizing fluorinated aldehydes underscores its importance in pharmaceutical research and development. As our understanding of molecular interactions continues to evolve,3-Fluoro-4-(trifluoromethoxy)benzaldehyde is likely to remain at the forefront of efforts aimed at discovering novel therapeutics that address unmet medical needs.

• 351-54-2(3-Fluoro-4-methoxybenzaldehyde)
• 86256-48-6(4-Fluoro-3-(trifluoromethoxy)benzaldehyde)
• 616229-09-5(1,1':4',1''-Terphenyl, 3,4''-difluoro-4-(trifluoromethoxy)-)
• 1261797-30-1(2-fluoro-4-[4-(trifluoromethoxy)phenyl]phenol)
• 524030-03-3(1,1'-Biphenyl, 3-fluoro-4'-methyl-4-(trifluoromethoxy)-)
• 886498-89-1(3-Fluoro-4-(trifluoromethoxy)benzoic acid)
• 1214379-56-2(4-(difluoromethoxy)-3-fluorobenzaldehyde)
• 1159512-58-9(2-fluoro-3-(trifluoromethoxy)benzaldehyde)
• 1352999-98-4(3-Fluoro-5-(trifluoromethoxy)benzaldehyde)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)